<DOC>
	<DOCNO>NCT01856855</DOCNO>
	<brief_summary>This study investigate safety , tolerability , effectiveness give high dose part prostate contain cancer give standard radiation dose entire prostate . The investigator hypothesize treatment technique effectively control prostate cancer minimize side effect .</brief_summary>
	<brief_title>Pilot Trial Evaluating Stereotactic Body Radiotherapy With Integrated Boost Clinically Localized Prostate Cancer ( RAD 1203 )</brief_title>
	<detailed_description>Objectives : Primary -Clinically assess early toxicity SBRT integrate boost clinically localized prostate cancer Secondary - Determine technical feasibility stereotactic body radiotherapy ( SBRT ) integrate boost clinically localized prostate cancer - Determine treatment plan dosimetric feasibility - Evaluate treatment delivery quality assurance - Clinically assess early efficacy , late toxicity , quality life patient receive SBRT integrate boost clinically localized prostate cancer Patients undergo 5 total radiation treatment 7-17 day period . Patients ask complete American Urological Association Symptom Index ( AUA SI ) , Sexual Health Inventory Men ( SHIM ) , Expanded Prostate Index Composite ( EPIC ) questionnaires . The EPIC assess bowel , urinary , sexual function . These questionnaire complete following time point : Baseline , AUA SI collect last day treatment , every 3 month first year follow start radiation , every 6 month year 2 . After completion study therapy , patient followed-up every 3 month first year , every 6 month year 2 .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>All patient must Histologically confirm prostate adenocarcinoma , biopsy obtain within twelve month patient registration NCCN risk category low , low , intermediate risk Combined Gleason score &lt; 7 PSA within three month enrollment &lt; 20ng/ml Clinical stage T1ac N0M0 clinical stage T2aN0M0 Life expectancy &gt; 5 year Risk malignant lymph node involvement &lt; 15 % calculate Partin table Karnofsky performance status ( KPS ) &gt; 60 Age &gt; 19 year Subjects give write informed consent History inflammatory bowel disease Prior radical prostate surgery , transurethral resection prostate ( TURP ) , prostate cryotherapy Patients use immunosuppressive medication medication may increase radiation toxicity methotrexate , sirolimus , tacrolimus , colchicine unable discontinue medication SBRT course . Use corticosteroid consider exclusion criterion . Platelet count &lt; 70 Patients unable discontinue antiplatelet anticoagulant medicine clopidogrel , dabigatran , warfarin , low molecular weight heparin . Use aspirin exclusion criterion . PreSBRT prostate volume &gt; 120 cc estimate transrectal ultrasound time prostate biopsy ( TRUS biopsy ) . Risk malignant lymph node involvement &gt; 15 % calculate Partin table .</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Prostate Adenocarcinoma</keyword>
	<keyword>Radiation</keyword>
	<keyword>SBRT</keyword>
	<keyword>Stereotactic Body Radiation Therapy</keyword>
</DOC>